Size frequency distributions of abnormal protein deposits in Alzheimer's disease and variant Creutzfeldt-Jakob disease

Folia Neuropathologica

Volumn 45, Issue 3, 2007, Pages 108-114

  Armstrong, Richard A ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Log normal distribution; Protein deposit growth; Size distribution; Surface diffusion; amyloid (A )

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NORMAL DISTRIBUTION; PROTEIN LOCALIZATION; STATISTICAL ANALYSIS; VARIANT CREUTZFELDT JAKOB DISEASE;

EID: 34948901359     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Armstrong RA. Is the clustering of β-amyloid (Aβ) deposits in the frontal cortex of Alzheimer patients determined by blood vessels? Neurosci Lett 1995; 195: 121-124.
2. Armstrong RA. β-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord 1998; 9: 227-238.
3. Armstrong RA. Do β-amyloid (Aβ) deposits in patients with Alzheimer's disease and Down's syndrome grow according to the log-normal model? Neurosci Lett 1999; 261: 97-100.
4. Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer's disease. Folia Neuropathol 2006; 44: 1-11.
5. Armstrong RA. Classic β-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer's disease. Curr Neurovasc Res 2006; 3: 289-294.
6. Armstrong RA, Myers D, Smith CU. Factors determining the size frequency distribution of β-amyloid (Aβ) deposits in Alzheimer's disease. Exp Neurol 1997; 145: 574-579.
7. Armstrong RA, Lantos PL, Cairns NJ. The spatial patterns of prion protein deposits in Creutzfeldt-Jakob disease: comparison with β-amyloid deposits in Alzheimer's disease. Neurosci Lett 2001; 298: 53-56.
8. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Quantification of vacuolation ("spongiform change"), surviving neurones and prion protein deposition in eleven cases of variant Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2002; 28: 129-135.
9. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Laminar distribution of the pathological changes in the cerebral cortex in variant Creutzfeldt-Jakob disease (vCJD). Folia Neuropathol 2002; 40: 165-171.
10. Armstrong RA, Lantos PL, Ironside JW, Cairns NJ. Differences in the density and spatial distribution of florid and diffuse plaques in variant Creutzfeldt-Jakob disease (vCJD). Clin Neuropathol 2003; 22: 209-214.
11. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Florid prion protein (PrP) plaques in patients with variant Creutzfeldt-Jakob disease (vCJD) are spatially related to blood vessels. Neurosci Res Communs 2003; 32: 29-36.
12. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Size frequency distribution of prion protein (PrP) aggregates in variant Creutzfeldt-Jakob disease. J Neural Transm 2005; 112: 1565-1573.
13. Benes FM, Reifel JL, Majocha RE, Marotta CA. Evidence for a diffusional model of Alzheimer amyloid A4 (β amyloid) during neuritic plaque formation. Neuroscience 1989; 33: 483-488.
14. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-259.
15. Carrotta R, Manno M, Bulone D, Martorana V, San Biagio PL. Protofibril formation of amyloid beta-protein at low pH via a non-cooperative elongation mechanism. J Biol Chem 2005; 280: 30001-30008.
16. Christopeit T, Hortschansky P, Schroeckh V, Guhrs K, Zandomeneghi G, Fandrich M. Mutagenic analysis of the nucleation propensity of oxidized Alzheimer's beta-amyloid peptide. Protein Sci 2005; 14: 2125-2131.
17. Freixes M, Puig B, Rodríguez A, Torrejón-Escribano B, Blanco R, Ferrer I. Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 2004; 108: 295-301.
18. Ha C, Park CB. Ex situ atomic force microscopy analysis of beta-amyloid self-assembly and deposition on a synthetic template. Langmuir 2006; 22: 6977-6985.
19. El Hachini KH, Cervenakova L, Brown P, Goldfarb LG, Rubenstein R, Gajdusek DC, Foncin JF. Mixed features of Alzheimer's disease and Creutzfeldt-Jakob disease in a family with a presenilin 1 mutation in chromosome 14. Amyloid: Int J Exp Clin Invest 1996; 3: 223-233.
20. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullota F, Budka H. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 1998; 96: 116-122.
21. Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997; 66: 385-407.
22. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thoma DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj A, Ironside JW, Lantos PL, Collinge J. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-189.
23. Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A 1995; 92: 3586-3590.
24. Ironside JW, Head MW, Bell JE, McCardle L, Will RG. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology 2000; 37: 1-9.
25. Kawai M, Cras P, Perry G. Serial reconstruction of β-protein amyloid plaques: relationship to microvessels and size distribution. Brain Res 1992; 592: 278-282.
26. Kim JR, Muresan A, Lee KY, Murphy RM. Urea modulation of beta-amyloid fibril growth: experimental studies and kinetic models. Protein Sci 2004; 13: 2888-2898.
27. Krasemann S, Groschup MH, Harmeyer S, Hunsmann G, Bodemer W. Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med 1996; 2: 725-734.
28. Kuner P, Bohrmann B, Tjernberg LO, Näslund J, Huber G, Celenk S, Gruninger-Leitch F, Richards JG, Jakob-Roetne R, Kemp JA, Nordstedt C. Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands. J Biol Chem 2000; 275: 1673-1678.
29. Li G, Zhou P, Shao Z, Xie X, Chen X, Wang H, Chunyu L, Yu T. The natural silk spinning process. A nucleation-dependent aggregation mechanism? Eur J Biochem 2001; 268: 6600-6606.
30. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A 1992; 89: 5462-5466.
31. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
32. Muramoto T, Kitamoto T, Koga H, Tateishi J. The coexistence of Alzheimer's disease and Creutzfeldt-Jakob disease in a patient with dementia with long duration. Acta Neuropathol (Berl) 1992; 84: 686-689.
33. Nguyen HD, Hall CK. Kinetics of fibril formation by polyalanine peptides. J Biol Chem 2005; 280: 9074-9082.
34. Preusser M, Strobel T, Gelpi E, Eiler M, Broessner G, Schmutzhard E, Budka H. Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. J Neurol Neurosurg Psychiatry 2006; 77: 413-416.
35. Pollard JH. Numerical and Statistical Technique. Cambridge University Press, Cambridge 1979.
36. Robbins EM, Betensky RA, Domnitz SB, Purcell SM, Garcia-Alloza M, Greenberg C, Rebeck GW, Hyman BT, Greenberg SM, Frosch MP, Bacskai BJ. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J Neurosci 2006; 26: 365-371.
37. Spargo E, Luthert PJ, Anderton BH, Bruce M, Smith D, Lantos PL. Antibodies raised against different portions of A4 protein identify a subset of plaques in Down's syndrome. Neurosci Lett 1990; 115: 345-350.
38. Stanley HE, Buldyrev SV, Cruz L, Gomez-Isla T, Havlin S, Hyman BT, Knowles R, Urbanc B, Wyart C. Statistical physics and Alzheimer's disease. Physica A 1998; 249: 460-471.
39. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstraten P. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurology 1988; 38: 359-364.
40. Urbanc B, Cruz L, Buldyrev SV, Havlin S, Irizarry MC, Stanley HE, Hyman BT. Dynamics of plaque formation in Alzheimer's disease. Biophys J 1999a; 76: 1330-1334.
41. Urbanc B, Cruz L, Buldyrev SV, Havlin S, Hyman BT, Stanley HE. Dynamic feedback in an aggregation-disaggregation model. Physic Rev E 1999b; 60: 2120-2126.
42. Veerhuis R, Boshuizen RS, Morbin M, Mazzoleni G, Hoozemans JJ, Langedijk JP, Tagliavini F, Langeveld JP, Eikelenboom P. Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiol Dis 2005; 19: 273-282.
43. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-925.
44. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 1992; 141: 249-259.